Strides Secures FDA Approval for Fluoxetine Tabs
With the approval of the Fluoxetine Tabs 60 mg strength, the company is now positioned to offer a complete portfolio of Fluoxetine across Capsules and Tablets in 10 mg, 20 mg, and 60 mg strengths.
Global Pharma | 17/09/2024 | By Aishwarya | 620
Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.
Global Pharma | 17/09/2024 | By Aishwarya | 798
Zydus Signs Licensing and Supply Agreement with Viwit Pharmaceuticals
As per the terms of the agreement, Viwit will be responsible for ANDA submission, manufacturing and supplying the generic versions of GADAVISTTM and DOTAREM, following the receipt of requisite regulatory approval.
Global Pharma | 16/09/2024 | By Aishwarya | 778
Refeyn Establishes New Mass Photometry Scientific Advisory Board
The new Scientific Advisory Board will convene regularly to explore and evaluate the transformative potential of mass photometry in critical customer workflows.
Global Pharma | 16/09/2024 | By Aishwarya | 750
Arrowhead Pharmaceuticals Secures FDA Breakthrough Therapy Designation for Plozasiran
Arrowhead intends to submit a New Drug Application to the FDA by year-end 2024 and plans to seek regulatory approval with additional global regulatory authorities thereafter.
Global Pharma | 13/09/2024 | By Aishwarya | 549
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza with ENHANZE
Tecentriq Hybreza can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) infusion of Tecentriq (atezolizumab).
Global Pharma | 13/09/2024 | By Aishwarya | 554
Sunsure Energy to Energise Lupin's Tarapur Facility with 21 MW Solar Power
Through this agreement, Sunsure will supply solar power to Lupin’s Tarapur facility in India, sourced from its 100 MW (150 MWp) solar plant in Solapur.
Global Pharma | 13/09/2024 | By Aishwarya | 830
Varda Works with SSPC to Study Microgravity Crystallization
Varda and SSPC researchers based at the University of Limerick and the Mathematics Applications Consortium for Science and Industry (MACSI), Ireland, are collaborating on research that focuses on developing mathematical models for better understanding of how gravity influences crystallization and the resulting polymorphic outcomes.
Global Pharma | 12/09/2024 | By Aishwarya | 606
Johnson & Johnson Gets US FDA Approval for TREMFYA
TREMFYA is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.
Global Pharma | 12/09/2024 | By Aishwarya | 466
GenNext and Agilent to Boost High-Value Decision Making in Biopharmaceutical Research
The integration of GenNext's AutoFox Protein Footprinting System with Agilent's 6560 Ion Mobility Quadrupole Time-of-Flight (IM-QTOF) LC/MS System presents an unparalleled approach to detailed protein structure analysis and biomolecular interaction studies.
Global Pharma | 12/09/2024 | By Aishwarya | 579
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy